Alberto Alonso-Babarro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alberto Alonso-Babarro has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Eduardo Bruera
From La Paz University Hospital, Madrid Autonomous University; Palliative Home Care Team, Area Sanitaria 5, Madrid, Spain; and The University of Texas MD Anderson Cancer Center, Houston, TX
2 shared publications- Isabel Torres-Vigil
Graduate College of Social Work, University of Houston, Houston, Texas, USA
2 shared publications A Cos Blanco
1 shared publicationA Moya
1 shared publicationC Gómez Candela
1 shared publication- Concepcion Prados
Unidad de Infecciones Respiratorias, Servicio de Neumología, Hospital Universitario La Paz, Madrid, España
1 shared publication
Latest Publications
- 8 June 2023
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (8) , 3304-3331
Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients
The tumor biology of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) promotes the development of central nervous system (CNS) metastases, with 25% of patients with HER2-positive BC developing CNS metastases. Furthermore, the incidence of HER2-positive BC brain metastases has increased in the last decades, likely because of the improved survival with targeted therapies and better detection methods. Brain metastases are detrimental to quality of life and survival and represent a challenging clinical problem, particularly in elderly women, who comprise a substantial proportion of patients diagnosed with BC and often have comorbidities or an age-related decline in organ function. Treatment options for patients with BC brain metastases include surgical resection, whole-brain radiation therapy, stereotactic radiosurgery, chemotherapy, and targeted agents. Ideally, local and systemic treatment decisions should be made by a multidisciplinary team, with input from several specialties, based on an individualized prognostic classification. In elderly patients with BC, additional age-associated conditions, such as geriatric syndromes or comorbidities, and the physiologic changes associated with aging, may impact their ability to tolerate cancer therapy and should be considered in the treatment decision-making process. This review describes the treatment options for elderly patients with HER2-positive BC and brain metastases, focusing on the importance of multidisciplinary management, the different points of view from the distinct disciplines, and the role of oncogeriatric and palliative care in this vulnerable patient group.
- 8 June 2023
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (8) , 3304-3331
Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients
The tumor biology of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) promotes the development of central nervous system (CNS) metastases, with 25% of patients with HER2-positive BC developing CNS metastases. Furthermore, the incidence of HER2-positive BC brain metastases has increased in the last decades, likely because of the improved survival with targeted therapies and better detection methods. Brain metastases are detrimental to quality of life and survival and represent a challenging clinical problem, particularly in elderly women, who comprise a substantial proportion of patients diagnosed with BC and often have comorbidities or an age-related decline in organ function. Treatment options for patients with BC brain metastases include surgical resection, whole-brain radiation therapy, stereotactic radiosurgery, chemotherapy, and targeted agents. Ideally, local and systemic treatment decisions should be made by a multidisciplinary team, with input from several specialties, based on an individualized prognostic classification. In elderly patients with BC, additional age-associated conditions, such as geriatric syndromes or comorbidities, and the physiologic changes associated with aging, may impact their ability to tolerate cancer therapy and should be considered in the treatment decision-making process. This review describes the treatment options for elderly patients with HER2-positive BC and brain metastases, focusing on the importance of multidisciplinary management, the different points of view from the distinct disciplines, and the role of oncogeriatric and palliative care in this vulnerable patient group.
- Open Access
- 22 March 2016
- Published by Springer Nature in BMC Palliative Care
- Vol. 15 (1) , 1-9
HOLD study (Home care Obstructive Lung Disease): natural history of patients with advanced COPD
Chronic obstructive pulmonary disease (COPD) is the fourth cause of death in western countries. Its final stage has clearly been forgotten by medical research in recent years. There exists consensus regarding the need to integrate palliative care in assisting these patients, but the difficulty in establishing a prognosis for the disease, establishing limits for life support measures, the lack of information about the disease’s natural course and ignorance as to the most effective health-care structure for these patients’ palliative treatment may be responsible for their late inclusion or non-inclusion in specific programmes. The main purpose of this work is to find out the natural background of patients with stage IV COPD and the main prognostic factors that influence these patients’ survival. Prospective observational study of a home patient cohort with stage IV COPD sent from Neumology consultations and Palliative Care Unit in La Paz Hospital in Madrid and Primary Care Health Centres in the area to the palliative care home support team. The goal is to study socio-demographic variables, prognosis, nutritional status, use of health resources, perceived quality of life, functionality, main symptomatology, use and effectiveness of opioids, adherence to treatment, prognostic information regarding the disease, information given by professionals, advance directives, social backup requirements and overburden level of the main caregiver. The HOLD study is a project aimed at finding out the prognostic factors and evolution of the disease COPD in its most advanced stage. The final goal is to improve the health and quality of life, in a personalised, integral way up to end of life and explore and foster communication with patients, as well as their participation and collaboration in decision-taking. The HOLD study can help us better understand what these patients’ real palliative and care needs are, in order to more efficiently organise their treatment at end of life.
- 22 March 2016
- Published by Springer Nature in BMC Palliative Care
- Vol. 15 (1) , 1-9
Open AccessHOLD study (Home care Obstructive Lung Disease): natural history of patients with advanced COPD
Chronic obstructive pulmonary disease (COPD) is the fourth cause of death in western countries. Its final stage has clearly been forgotten by medical research in recent years. There exists consensus regarding the need to integrate palliative care in assisting these patients, but the difficulty in establishing a prognosis for the disease, establishing limits for life support measures, the lack of information about the disease’s natural course and ignorance as to the most effective health-care structure for these patients’ palliative treatment may be responsible for their late inclusion or non-inclusion in specific programmes. The main purpose of this work is to find out the natural background of patients with stage IV COPD and the main prognostic factors that influence these patients’ survival. Prospective observational study of a home patient cohort with stage IV COPD sent from Neumology consultations and Palliative Care Unit in La Paz Hospital in Madrid and Primary Care Health Centres in the area to the palliative care home support team. The goal is to study socio-demographic variables, prognosis, nutritional status, use of health resources, perceived quality of life, functionality, main symptomatology, use and effectiveness of opioids, adherence to treatment, prognostic information regarding the disease, information given by professionals, advance directives, social backup requirements and overburden level of the main caregiver. The HOLD study is a project aimed at finding out the prognostic factors and evolution of the disease COPD in its most advanced stage. The final goal is to improve the health and quality of life, in a personalised, integral way up to end of life and explore and foster communication with patients, as well as their participation and collaboration in decision-taking. The HOLD study can help us better understand what these patients’ real palliative and care needs are, in order to more efficiently organise their treatment at end of life.
- 29 September 2011
- Published by Elsevier in Atencion Primaria
- Vol. 43 (11) , 575-576
La importancia de evaluar adecuadamente el dolor
- 29 September 2011
- Published by Elsevier in Atencion Primaria
- Vol. 43 (11) , 575-576
La importancia de evaluar adecuadamente el dolor
- 20 March 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (9) , 1159-1167
Can This Patient Be Discharged Home? Factors Associated With At-Home Death Among Patients With Cancer
Purpose: The purpose of this study was to identify factors associated with at-home death among patients with advanced cancer and create a decision-making model for discharging patients from an acute-care hospital. Patients and Methods: We conducted an observational cohort study to identify the association between place of death and the clinical and demographic characteristics of patients with advanced cancer who received care from a palliative home care team (PHCT) and of their primary caregivers. We used logistic regression analysis to identify the predictors of at-home death. Results: We identified 380 patients who met the study inclusion criteria; of these, 245 patients (64%) died at home, 72 (19%) died in an acute-care hospital, 60 (16%) died in a palliative care unit, and three (1%) died in a nursing home. Median follow-up was 48 days. We included the 16 variables that were significant in univariate analysis in our decision-making model. Five variables predictive of at-home death were retained in the multivariate analysis: caregiver's preferred place of death, patients' preferred place of death, caregiver's perceived social support, number of hospital admission days, and number of PHCT visits. A subsequent reduced model including only those variables that were known at the time of discharge (caregivers' preferred place of death, patients' preferred place of death, and caregivers' perceived social support) had a sensitivity of 96% and a specificity of 81% in predicting place of death. Conclusion: Asking a few simple patient- and family-centered questions may help to inform the decision regarding the best place for end-of-life care and death.
- 20 March 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (9) , 1159-1167
Can This Patient Be Discharged Home? Factors Associated With At-Home Death Among Patients With Cancer
Purpose: The purpose of this study was to identify factors associated with at-home death among patients with advanced cancer and create a decision-making model for discharging patients from an acute-care hospital. Patients and Methods: We conducted an observational cohort study to identify the association between place of death and the clinical and demographic characteristics of patients with advanced cancer who received care from a palliative home care team (PHCT) and of their primary caregivers. We used logistic regression analysis to identify the predictors of at-home death. Results: We identified 380 patients who met the study inclusion criteria; of these, 245 patients (64%) died at home, 72 (19%) died in an acute-care hospital, 60 (16%) died in a palliative care unit, and three (1%) died in a nursing home. Median follow-up was 48 days. We included the 16 variables that were significant in univariate analysis in our decision-making model. Five variables predictive of at-home death were retained in the multivariate analysis: caregiver's preferred place of death, patients' preferred place of death, caregiver's perceived social support, number of hospital admission days, and number of PHCT visits. A subsequent reduced model including only those variables that were known at the time of discharge (caregivers' preferred place of death, patients' preferred place of death, and caregivers' perceived social support) had a sensitivity of 96% and a specificity of 81% in predicting place of death. Conclusion: Asking a few simple patient- and family-centered questions may help to inform the decision regarding the best place for end-of-life care and death.
- 3 February 2010
- Published by SAGE Publications in Palliative Medicine
- Vol. 24 (5) , 486-492
At-home palliative sedation for end-of-life cancer patients
Using a decision-making and treatment checklist developed to facilitate the at-home palliative sedation process, we assessed the incidence and efficacy of palliative sedation for end-of-life cancer patients with intractable symptoms who died at home. We retrospectively reviewed the medical records of 370 patients who were followed by a palliative home care team. Twenty-nine of 245 patients (12%) who died at home had received palliative sedation. The mean age of the patients who received palliative sedation was 58 ± 17 years, and the mean age of the patients who did not receive palliative sedation was 69 ± 15 years (p = 0.002). No other differences were detected between patients who did or did not receive palliative sedation. The most common indications for palliative sedation were delirium (62%) and dyspnea (14%). Twenty-seven patients (93%) received midazolam for palliative sedation (final mean dose of 74 mg), and two (7%) received levomepromazine (final mean dose of 125 mg). The mean time between palliative sedation initiation and time of death was 2.6 days. In 13 of the cases (45%), the palliative sedation decision was made with the patient and his or her family members, and in another 13 patients (45%), the palliative sedation decision was made only with the patient’s family members. We concluded that palliative sedation may be used safely and efficaciously to treat dying cancer patients with refractory symptoms at home.
- 3 February 2010
- Published by SAGE Publications in Palliative Medicine
- Vol. 24 (5) , 486-492
At-home palliative sedation for end-of-life cancer patients
Using a decision-making and treatment checklist developed to facilitate the at-home palliative sedation process, we assessed the incidence and efficacy of palliative sedation for end-of-life cancer patients with intractable symptoms who died at home. We retrospectively reviewed the medical records of 370 patients who were followed by a palliative home care team. Twenty-nine of 245 patients (12%) who died at home had received palliative sedation. The mean age of the patients who received palliative sedation was 58 ± 17 years, and the mean age of the patients who did not receive palliative sedation was 69 ± 15 years (p = 0.002). No other differences were detected between patients who did or did not receive palliative sedation. The most common indications for palliative sedation were delirium (62%) and dyspnea (14%). Twenty-seven patients (93%) received midazolam for palliative sedation (final mean dose of 74 mg), and two (7%) received levomepromazine (final mean dose of 125 mg). The mean time between palliative sedation initiation and time of death was 2.6 days. In 13 of the cases (45%), the palliative sedation decision was made with the patient and his or her family members, and in another 13 patients (45%), the palliative sedation decision was made only with the patient’s family members. We concluded that palliative sedation may be used safely and efficaciously to treat dying cancer patients with refractory symptoms at home.
- 2 November 2004
- Vol. 19 (5) , 281-5
[Assessment of home parenteral nutrition programme in terminal oncological patients].
The assessment of the acceptance of the diets served at the hospital allows the introduction of adjustments to improve the quality of the service provided to hospitalized patients by preventing the complications derived from incorrect nutrition and enhancing their stay in hospital. The goal of the present study was to analyze the acceptance of the menus offered by the Hospital's catering service. Menus provided by the catering service of the "Sant Joan de Reus" University Hospital. A total of 160 tray meals consumed were assessed, all chosen at random and corresponding to standard diets and special diets, including puréed food. The assessment was made by two dieticians in the hospital's kitchens. A visual scale was used with the following scores: 0 for a full plate, 1 for residual food amounting to over 75%, 2 from 50% to 75%, 3 more than or equal to 25% and 4 for empty plates. A total of 68 trays containing a standard diet were analyzed, together with 34 containing special diets and 41 with puréed food. The remains on 36 different courses from the standard diet were analyzed. The mean acceptance score was 3.01 +/- 1.30 in the case of the first courses, 3.24 +/- 1.11 in second courses and 3.53 +/- 0.96 for the desserts. As for special diets, a total of 27 different courses were analyzed. The mean acceptance score was 2.87 +/- 1.38 in the case of the first courses, 3.02 +/- 1.27 in second courses and 3.49 +/- 1.22 for the desserts. The first courses of puréed diets received the worst score of all the dishes served, although the overall mean score was good, 2.76 +/- 1.5. In general, a good level of acceptance has been observed for the set meals served in the hospital. Knowing which courses have lower acceptance scores allows changes to be proposed to the hospital menus, with their replacement by others with foreseeably better acceptance.
- 2 November 2004
- Vol. 19 (5) , 281-5
[Assessment of home parenteral nutrition programme in terminal oncological patients].
The assessment of the acceptance of the diets served at the hospital allows the introduction of adjustments to improve the quality of the service provided to hospitalized patients by preventing the complications derived from incorrect nutrition and enhancing their stay in hospital. The goal of the present study was to analyze the acceptance of the menus offered by the Hospital's catering service. Menus provided by the catering service of the "Sant Joan de Reus" University Hospital. A total of 160 tray meals consumed were assessed, all chosen at random and corresponding to standard diets and special diets, including puréed food. The assessment was made by two dieticians in the hospital's kitchens. A visual scale was used with the following scores: 0 for a full plate, 1 for residual food amounting to over 75%, 2 from 50% to 75%, 3 more than or equal to 25% and 4 for empty plates. A total of 68 trays containing a standard diet were analyzed, together with 34 containing special diets and 41 with puréed food. The remains on 36 different courses from the standard diet were analyzed. The mean acceptance score was 3.01 +/- 1.30 in the case of the first courses, 3.24 +/- 1.11 in second courses and 3.53 +/- 0.96 for the desserts. As for special diets, a total of 27 different courses were analyzed. The mean acceptance score was 2.87 +/- 1.38 in the case of the first courses, 3.02 +/- 1.27 in second courses and 3.49 +/- 1.22 for the desserts. The first courses of puréed diets received the worst score of all the dishes served, although the overall mean score was good, 2.76 +/- 1.5. In general, a good level of acceptance has been observed for the set meals served in the hospital. Knowing which courses have lower acceptance scores allows changes to be proposed to the hospital menus, with their replacement by others with foreseeably better acceptance.
- 1 January 2003
- Published by Elsevier in Atencion Primaria
- Vol. 32 (6) , 390-392
Evolución del consumo de opioides en un área de Madrid desde 1997 a 2001
- 1 January 2003
- Published by Elsevier in Atencion Primaria
- Vol. 32 (6) , 390-392
Evolución del consumo de opioides en un área de Madrid desde 1997 a 2001